Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study

This publication has 23 references indexed in Scilit:

• A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin
  Journal of Cardiovascular Pharmacology and Therapeutics, 1998
• Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.
  The American Journal of Cardiology, 1998
• Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (“Statins”) in Familial Combined Hyperlipidemia
  The American Journal of Cardiology, 1998
• The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients
  PharmacoEconomics, 1998
• 1.P.178 Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia
  Atherosclerosis, 1997
• 2.P.17 Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin
  Atherosclerosis, 1997
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
  The American Journal of Cardiology, 1997
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Drug therapy of hyperlipidemia
  Current Problems in Cardiology, 1992
• Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
  JAMA, 1988